SHR-A1921 + carboplatin

**SHR-A1921 + carboplatin** is an investigational combination therapy targeting advanced solid tumors, primarily in the context of clinical trials. SHR-A1921 is a novel antibody-drug conjugate (ADC) that specifically targets the cell-surface glycoprotein Trop-2, which is highly expressed in a range of epithelial cancers. SHR-A1921 consists of a proprietary IgG1 monoclonal antibody linked via a cleavable tetrapeptide-based linker to SHR9265—a potent DNA topoisomerase I inhibitor and novel derivative of exatecan—serving as the ADC payload. The combination with **carboplatin**, a platinum-based chemotherapeutic agent, is under early-phase clinical investigation for the treatment of advanced solid tumors including non-small cell lung cancer and platinum-resistant ovarian cancer. Preclinical and clinical studies suggest that SHR-A1921 exhibits high binding affinity for Trop-2, potent bystander killing effect, favorable pharmacokinetics, and manageable safety profile, with the potential to improve outcomes in patients with resistant or heavily pretreated cancers[2][4][6][8][1]. The combination with carboplatin aims to leverage complementary mechanisms of anti-tumor activity.

Other names

tizetatug rezetecan + carboplatin